Hemophilia
Hemophilia
Advertisement
Erica Mamauag, MDHemophilia | April 9, 2024
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
View More
Patrick DalyHemophilia | April 1, 2024
The US FDA has approved an expanded indication for IXINITY to control bleeding in all patients with hemophilia B.
Patrick DalyHemophilia | February 21, 2024
Desmopressin with FVIII during operations was reportedly feasible and safe in patients with nonsevere hemophilia A.
Patrick DalyHemophilia | February 14, 2024
Patients with hemophilia A or B had low rates of VTE after total joint replacement despite infrequent thromboprophylaxis use.
Patrick DalyHemophilia | February 8, 2024
Desmopressin was safe and effective for women with inherited bleeding disorders during both pregnancy and delivery.
Patrick DalyHemophilia | January 12, 2024
Health Canada approved fidanacogene elaparvovec, an adenoviral vector-based gene therapy for patients with hemophilia B.
Patrick DalyHemophilia | January 19, 2024
The FDA and EMA are expected to make decisions on once-weekly subcutaneous marstacimab for patients with hemophilia A or B.
Patrick DalyHemophilia | December 14, 2023
Large deletions in the FVIII gene (F8) were shown to be predictors of ITI therapy failure.
Patrick DalyHemophilia | December 14, 2023
Emicizumab plus ITI did not induce new safety signals in patients with hemophilia A.
Patrick DalyHemophilia | December 14, 2023
A single infusion of AAV-HLP-hFVIII-V3 induced stable FVIII expression over five years.
Patrick DalyHemophilia | December 14, 2023
Women with inherited bleeding disorders may need prophylaxis.
Patrick DalyHemophilia | December 14, 2023
First patient treated with hemophilia A gene therapy demonstrates "promising" outcomes.
Cailin ConnerHemophilia | August 25, 2023
A study investigated clinical outcomes before and after pharmacokinetic (PK)-guided dosing for hemophilia.
Cailin ConnerHemophilia | August 25, 2023
Genicular artery embolization showed promising results in reducing synovial hyperemia in patients with hemophilia.
Patrick DalyHemophilia | August 25, 2023
Poor bleeding rates seen despite flawed data across studies on congenital hemophilia A without inhibitors on FVIII treatment.
Patrick DalyHemophilia | August 25, 2023
Simoctocog alfa was effective as prophylaxis or treatment for bleeding in treatment-naïve patients with severe hemophilia A.
Patrick DalyHemophilia | August 25, 2023
Fitusiran significantly reduced the annualized bleeding rate in patients with severe hemophilia, even those with inhibitors.
The Fellow on CallThe Fellow on Call | September 5, 2023
In this episode of The Fellow on Call: The Heme/Onc Podcast, the group closes out their hemophilia series.
The Fellow on CallThe Fellow on Call | September 5, 2023
The group delineates the acute management of hemophilia patients, particularly with factor replacement.
The Fellow on CallThe Fellow on Call | September 5, 2023
The group distinguishes between the two types of hemophilia: genetic and acquired.
Advertisement
Advertisement
Advertisement
Latest News

April 24, 2024